Content
@
0 reply
0 recast
0 reaction
Dan
@dberg
I read this article last year and thought “wow patent evergreening is terrible, how evil.” Turns out it’s not rly true. https://www.nytimes.com/2023/01/28/business/humira-abbvie-monopoly.html?smid=nytcore-ios-share&referringSource=articleShare
2 replies
0 recast
1 reaction
Dan
@dberg
When a company files 100+ patents on a drug, most of them aren’t on the key active molecule. Lots are for manufacturing, method of treatment, etc. The patents filed on the key molecule expire just as they always do, so generics can still come to market. The patents aren’t what’s truly delaying competition.
1 reply
0 recast
1 reaction
SonOfMosiah
@sonofmosiah.eth
What changed your perspective?
1 reply
0 recast
0 reaction